Calporta, Started by Avalon Ventures-GSK, Is Acquired by Merck

Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired?but not by GSK. Instead, the company, Calporta Therapeutics, is being absorbed by Merck (NYSE: MRK), which is interested in its preclinical work on potential treatments for lysosomal storage and neurodegenerative diseases, including [?]